Log in to search using one of your social media accounts:

 

Certain Foods May Impact Timing of Menopause
TUESDAY, May 1, 2018 -- Intake of some food groups and nutrients may affect the timing of menopause, according to a study published online April 30 in the Journal of Epidemiology& Community Health. Yashvee Dunneram, from the University of Leeds... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

Clinically Significant Anxiety Tied to Subsequent Dementia Risk
TUESDAY, May 1, 2018 -- Clinically significant anxiety in midlife is associated with increased subsequent dementia risk over an interval of at least 10 years, according to a review published online April 30 in BMJ Open. Amy Gimson, from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

Centene to offer $2.6 billion in stock to fund acquisition
Managed care provider Centene Corp. has announced a $2.6 billion offering of common stock with net proceeds going to help finance its $3.75 billion purchase of Fidelis Care. The offering will be led by Barclays, Citigroup, Wells Fargo Securities, Evercore ISI and SunTrust Robinson Humphrey as the book-running managers, according to a release. Centene also will grant the underwriters an option to purchase up to an additional $260 million in shares of common stock. Th e acquisition to acquire Fidelis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 1, 2018 Category: Pharmaceuticals Authors: Vince Brennan Source Type: news

Pfizer blames sales miss on ‘customer buying patterns’
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 1, 2018 Category: Pharmaceuticals Source Type: news

Regeneron And Express Scripts Reach A Deal On Embattled Cholesterol Drug
Regeneron and Sanofi are cutting the price they charge pharmacy benefit manager Express Scripts for their cholesterol medicine, Praluent. In return, Express Scripts will remove almost all restrictions on the medicine, and make it cheaper for patients. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 1, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:REGN NYSE:SNY NASDAQ:ESRX Source Type: news

George Church, CRISPR Pioneer, Embraces Alternative Tech In Project To Recode A Human Genome
George Church, a Harvard scientist who pioneered the use of the enzyme CRISPR to edit the genes of human cells, will use an alternative, older technology in an effort to recode an entire human genome in hundreds of thousands of locations in order to make it immune to viruses. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 1, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:CLLS Source Type: news

Sanofi slashes price of wannabe-blockbuster cholesterol drug
Sales of Praluent have been hurt by the campaign to limit US pharmaceuticals costs (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 1, 2018 Category: Pharmaceuticals Source Type: news

LabCorp CEO tells analysts he sees the company's partnership with Walgreens expanding
Laboratory Corporation of America Holdings  expects its partnership with Walgreens to expand further, placing even more of the former's patient service centers into the drugstore chain's locations, said CEO David King during a conference call with analysts. In fact, the concept could perhaps grow through relationships with retailers other than Walgreens, according to King's statements. King made the comment after answering an analysts' question about the recent expansion of the partnership, which… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 1, 2018 Category: Pharmaceuticals Authors: Jessica Seaman Source Type: news

Analysis links US government global health R & D funding to jobs, economic benefits across states
The Trump Administration's proposal to slash funding to fight global health threats like malaria, Ebola, and HIV/AIDS could cost states thousands of jobs and millions of dollars in economic investment and put the health of residents at risk, according to a new state-by-state analysis released today on Capitol Hill by the Global Health Technologies Coalition (GHTC). This first-of-its-kind analysis quantifies how federal funding to create vaccines and treatments to combat deadly global diseases also benefits American states. (Source: World Pharma News)
Source: World Pharma News - May 1, 2018 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

Patient Engagement and Experience Conference, 16-17 May
The conference brings together HCPs, patients, payers, government, pharma and industry under one roof to focus on patients’ engagement and experience of their treatment to improve the real-world use of medicines. Speaking at the conference   John Maughan, Head of Products for S3 Connected Health and Nagore Fernandez, Head of Patient Solutions for EUCAN at Ashfield will be co-presenting at 2:40pm on Day 1 of the conference. They will discuss how to deliver a personal and connected experience across human and digital interactions, applying behavioural science at scale, and using data to be agile, responsive and s...
Source: Ashfield Healthcare News - May 1, 2018 Category: Pharmaceuticals Authors: Jane Neale Tags: Ashfield Source Type: news

Kymriah ® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication - the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. (Source: World Pharma News)
Source: World Pharma News - May 1, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Life in Emergistan: Railing Against Big Pharma While Pouring Cash into Big Alcohol
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - May 1, 2018 Category: Emergency Medicine Tags: Life in Emergistan Source Type: news

April 2018 Briefing - Emergency Medicine
Here are what the editors at HealthDay consider to be the most important developments in Emergency Medicine for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Critical Care
Here are what the editors at HealthDay consider to be the most important developments in Critical Care for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Nephrology
Here are what the editors at HealthDay consider to be the most important developments in Nephrology for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Surgery
Here are what the editors at HealthDay consider to be the most important developments in Surgery for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Dermatology
Here are what the editors at HealthDay consider to be the most important developments in Dermatology for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Urology
Here are what the editors at HealthDay consider to be the most important developments in Urology for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Pediatrics
Here are what the editors at HealthDay consider to be the most important developments in Pediatrics for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Gastroenterology
Here are what the editors at HealthDay consider to be the most important developments in Gastroenterology for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Pain Management
Here are what the editors at HealthDay consider to be the most important developments in Pain Management for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Cardiology
Here are what the editors at HealthDay consider to be the most important developments in Cardiology for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Orthopedics
Here are what the editors at HealthDay consider to be the most important developments in Orthopedics for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - OBGYN & amp; Women's Health
Here are what the editors at HealthDay consider to be the most important developments in OBGYN& Women's Health for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Internal Medicine
Here are what the editors at HealthDay consider to be the most important developments in Internal Medicine for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Neurology
Here are what the editors at HealthDay consider to be the most important developments in Neurology for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Family Practice
Here are what the editors at HealthDay consider to be the most important developments in Family Practice for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Rheumatology
Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Radiology
Here are what the editors at HealthDay consider to be the most important developments in Radiology for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Anesthesiology
Here are what the editors at HealthDay consider to be the most important developments in Anesthesiology for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Nursing
Here are what the editors at HealthDay consider to be the most important developments in Nursing for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Allergy
Here are what the editors at HealthDay consider to be the most important developments in Allergy for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Pathology
Here are what the editors at HealthDay consider to be the most important developments in Pathology for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Cosmetic Surgery
Here are what the editors at HealthDay consider to be the most important developments in Cosmetic Surgery for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Psychiatry
Here are what the editors at HealthDay consider to be the most important developments in Psychiatry for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Diabetes & amp; Endocrinology
Here are what the editors at HealthDay consider to be the most important developments in Diabetes& Endocrinology for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

April 2018 Briefing - Otolaryngology
Here are what the editors at HealthDay consider to be the most important developments in Otolaryngology for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

An Alarm About Anthem's Proposed Cuts To Anesthesia Staff During Eye Surgery
Anthem ’s guidance if implemented, would increase the risk of complications during routine cataract surgery (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 1, 2018 Category: Pharmaceuticals Authors: Elaine Schattner, Contributor Tags: NYSE:ANTM Source Type: news

United Therapeutics to acquire competitor pharmaceutical company
United Therapeutics Corp. has reached a deal to acquire California-based SteadyMed Therapeutics Inc. in a deal valued at $216 million, a move that eliminates a competitive threat to the Maryland biotech by pulling it into its own corner. The Silver Spring drugmaker will acquire SteadyMed for $4.46 per share in cash at closing, plus an additional $2.63 per share in cash when the company reaches a milestone related to the commercialization of Trevyent, a development-stage drug-device combination product… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 1, 2018 Category: Pharmaceuticals Authors: Sara Gilgore Source Type: news

Lawmakers shelve edibles for sale at Hawaii's medical marijuana dispensaries
Lawmakers want to establish a working group that would study edibles before legalizing them for sale in dispensaries. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 1, 2018 Category: Pharmaceuticals Authors: Anna Hrushka Source Type: news

Pentec Health Celebrates 35th Anniversary
Company is renewing its focus on patient centered care and commitment to the local community(PRWeb May 01, 2018)Read the full story at http://www.prweb.com/releases/2018/05/prweb15455327.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 1, 2018 Category: Pharmaceuticals Source Type: news

Saint Luke ’s Cancer Institute Awarded National Pancreatic Cancer...
SLCI is one of only 36 centers in the nation to achieve this designation(PRWeb May 01, 2018)Read the full story at http://www.prweb.com/releases/2018/05/prweb15455265.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 1, 2018 Category: Pharmaceuticals Source Type: news

Orion Biotechnology Canada Appoints new Chief Financial Officer
Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that Jason Burke has been appointed Chief Financial Officer effective immediately.(PRWeb May 01, 2018)Read the full story at http://www.prweb.com/releases/2018/05/prweb15450972.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 1, 2018 Category: Pharmaceuticals Source Type: news

New High Performance 4-Laser Benchtop Flow Cytometer to be Launched by...
The NovoCyte Quanteon™ flow cytometer, a highly advanced benchtop instrument with 4 lasers and 25-color options, will be launched at CYTO 2018(PRWeb May 01, 2018)Read the full story at http://www.prweb.com/releases/2018/05/prweb15453143.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 1, 2018 Category: Pharmaceuticals Source Type: news

FetchMD Offering H-E-B Pharmacy Delivery to Further Enhance the House...
FetchMD clients in San Antonio and Austin will now be able to have H-E-B Pharmacy prescriptions delivered with no delivery fee.(PRWeb May 01, 2018)Read the full story at http://www.prweb.com/releases/2018/05/prweb15453455.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 1, 2018 Category: Pharmaceuticals Source Type: news

PDA Inaugural Conference Draws Participation of Seven National...
PDA offers first of its kind pharmacopoeia event.(PRWeb May 01, 2018)Read the full story at http://www.prweb.com/releases/2018/05/prweb15453348.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 1, 2018 Category: Pharmaceuticals Source Type: news

Benchworks CEO Finalist for Entrepreneur Of The Year ® 2018 Award...
CEO Thad Bench instrumental in creating award-winning agency(PRWeb May 01, 2018)Read the full story at http://www.prweb.com/releases/2018/05/prweb15452453.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 1, 2018 Category: Pharmaceuticals Source Type: news

Newton ’s Karyopharm to seek FDA approval for cancer drug after trial win
Newton-based Karyopharm Therapeutics said Monday that it plans to seek FDA approval for its lead cancer drug later this year following the success of a mid-stage trial involving patients who had not responded to several previous treatments. Karyopharm (Nasdaq: KPTI) said that 25 percent of multiple myeloma patients in the trial had responded to treatment with the drug, called selinexor. As a result, the company announced plans to seek accelerated approval from the FDA in the second half of 2018. Shares… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 30, 2018 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Monthly News Roundup - April 2018
Jynarque is First Approved Drug for Serious Genetic Kidney Disease The U.S. Food and Drug Administration (FDA) has approved Otsuka’s Jynarque (tolvaptan), a selective vasopressin V2-receptor antagonist, as the first medicine to slow kidney... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 30, 2018 Category: Pharmaceuticals Source Type: news

Gilead To Pay Verily $90 Million To Probe Immune Cells
Gilead Sciences will pay up to $90 million over three years to Verily to run a suite of tests on the white blood cells of patients with rheumatoid arthritis, inflammatory bowel disease, and lupus in the hopes of identifying which patients respond to existing drugs. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 30, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:GILD NASDAQ:GOOG Source Type: news